Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acetohydroxamic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 13/20 | 0.64 |
| ▸ | MMP13 | P45452 | 13/20 | 0.64 |
| ▸ | MMP9 | P14780 | 10/20 | 0.64 |
| ▸ | MMP1 | P03956 | 10/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 3/20 | 0.46 |
| ▸ | MMP8 | P22894 | 2/20 | 0.46 |
| ▸ | MMP7 | P09237 | 1/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3940026 | 0.82 | MMP9 (0.62) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL6502886 | 0.79 | ADAM17 (0.58) | ADAM17MMP13MMP9MMP1ALDH1A1 | |
| SCHEMBL3940955 | 0.79 | ADAM17 (0.64) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL6625851 | 0.78 | MMP13 (1.00) | ADAM17MMP13MMP9MMP1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3938354 | 0.78 | MMP13 (0.98) | ADAM17MMP13MMP9MMP1ALDH1A1 | |
| SCHEMBL6499171 | 0.77 | MMP9 (0.81) | ADAM17MMP13MMP9MMP1ALDH1A1 | |
| SCHEMBL6628728 | 0.77 | MMP9 (0.69) | ADAM17MMP13MMP9MMP1MMP2 | |
| Hydrochloric Acid SCHEMBL3946389 | 0.76 | MMP9 (0.68) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL3947833 | 0.76 | MMP9 (0.77) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL7397646 | 0.74 | MMP13 (0.52) | ADAM17MMP13MMP9MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488754-B2 | Method for the treatment of polycystic kidney disease | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | WYETH HOLDINGS CORPORATION | 2004-04-01 | — | — | US | disclosed |
| WO-2002083112-A2 | METHOD FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | WYETH HOLDINGS CORPORATION (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063672-A1 | Method for the treatment of polycystic kidney disease | PKD1, PKD2, PCSK6 | ADAM17 9/4885MMP13 246/4885MMP9 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.